CRBU

Caribou Biosciences (CRBU) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.

Deals

Caribou Biosciences Has $94.8 Million Left As It Weighs A Merger Or Liquidation

The company plans to halt development of both cancer therapies after financing became harder to secure.

Markets

Caribou Biosciences Plans To End Both CAR-T Programs, Cut Staff And Explore A Sale Or Merger

An 8-K puts restructuring costs at $15 million to $19 million, with Wedbush engaged as exclusive financial advisor.